Femtrace patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Oct, 2025

(2 years from now)

Femtrace is owned by Apil.

Femtrace contains Estradiol Acetate.

Femtrace has a total of 1 drug patent out of which 0 drug patents have expired.

Femtrace was authorised for market use on 20 August, 2004.

Femtrace is available in tablet;oral dosage forms.

Femtrace can be used as treatment of moderate to severe vasomotor symptoms associated with menopause.

The generics of Femtrace are possible to be released after 02 October, 2025.

Drugs and Companies using ESTRADIOL ACETATE ingredient

Market Authorisation Date: 20 August, 2004

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause


More Information on Dosage

FEMTRACE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic